Amy Rick

Amy Comstock Rick, J.D., is the Director of FDA’s Rare Disease Innovation Hub (the Hub). She serves in a cross-cutting role across FDA’s Center for Drug Evaluations and Research (CDER), Center for Devices and Radiological Health (CDRH), and Center for Biologics Evaluation and Research (CBER) to facilitate implementation of the Hub. She also works closely with centers to develop and carry out a rare disease strategic agenda. 

Prior to joining the FDA, Ms. Rick served as Principal Consultant at Leavitt Partners, focusing on health policy matters, with a primary focus on rare disease and medical product development. Before Leavitt Partners, she served as President and Chief Executive Officer of the Food and Drug Law Institute (FDLI), a non-profit organization dedicated to providing an innovative, open, balanced exchange of ideas and viewpoints across the field of food and drug law. 

Before joining FDLI, Ms. Rick was Chief Executive Officer of the Parkinson’s Action Network. Ms. Rick also served as President of the Coalition for the Advancement of Medical Research and on the Boards of Directors for Research America, the National Health Council, and the American Brain Coalition.

Ms. Rick had previous federal service as a career attorney at the U.S. Department of Education from 1988 to 1998, focusing primarily on the field of government ethics. She was the Senate-confirmed Director of the U.S. Office of Government Ethics from 2000 to 2003 and Associate Counsel to the President in the White House Counsel’s Office from 1998 to 2000. She received a Bachelor of Arts degree from Bard College and a Juris Doctor degree from the University of Michigan.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.